Rui Liu | Tumor Radiobiology | Best Researcher Award

Posted on by Pencis

Dr. Rui Liu | Tumor Radiobiology | Best Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

SCOPUS ID

GOOGLE SCHOLAR

🏥DR. RUI LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Rui Liu began her academic journey with a strong foundation in biomedical sciences, eventually earning a Ph.D. from a prestigious institution renowned for excellence in public health and molecular oncology. Her early research experiences centered on cellular biology and radiation mechanisms, which laid the groundwork for her specialization in tumor radiobiology and DNA damage repair (DDR).

🩺PROFESSIONAL ENDEAVORS

Currently serving as a Lecturer at the School of Public Health, Wenzhou Medical University, Dr. Liu has dedicated herself to cutting-edge cancer research. With over five years of hands-on laboratory experience, she has developed deep expertise in molecular biology, gene editing (CRISPR-Cas9), animal modeling, bioinformatics, and cellular imaging technologies. Her academic career reflects a balance between rigorous research and impactful teaching, mentoring the next generation of oncology researchers.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR RADIOBIOLOGY

Dr. Liu’s core research explores the molecular intricacies of radiotherapy resistance, with a focus on DNA damage repair pathways and ferroptosis in tumor cells. She has pioneered studies that unravel how long non-coding RNAs (lncRNAs) like MALAT1 influence cancer cell radiosensitivity, potentially leading to enhanced radiotherapy strategies. Her work contributes valuable insights into overcoming therapeutic resistance in breast cancer and other solid tumors.

🌍IMPACT AND INFLUENCE

Dr. Liu’s research has significantly advanced understanding in her field, evidenced by 445+ citations, an H-index of 12, and impactful publications in SCI-indexed journals. She is an active voice in the scientific community, engaging in collaborative research with Jilin University and contributing to national and provincial projects. Her affiliations with professional societies amplify her influence in radiological toxicology and environmental biophysics.

🏆 ACCOLADES AND RECOGNITION

Notable Awards:

  • 🎓 National Scholarship for Doctoral Excellence

  • 🌟 Recognition as a promising young investigator in radiobiology

🏆LEGACY AND FUTURE CONTRIBUTIONS

As an emerging leader in radiation oncology research, Dr. Liu aims to translate molecular findings into clinical applications that improve therapeutic outcomes. She mentors student researchers and continues to expand her interdisciplinary work on novel radiotherapy biomarkers, synthetic lethality, and non-coding RNA therapeutics. Her commitment ensures sustained contributions to precision oncology and translational cancer science.

🧬CONCLUSION

Dr. Rui Liu exemplifies the next generation of scientists transforming cancer treatment through molecular radiobiology. With a robust publication record, interdisciplinary collaborations, and active academic service, she is poised to leave a lasting impact on oncology research, education, and clinical innovation. Her ongoing efforts promise to redefine therapeutic strategies for radiation-resistant cancers.

📊🔬NOTABLE PUBLICATION:

Title: Metal ions overloading and cell death
Authors: Y. Lai, F. Gao, R. Ge, R. Liu, S. Ma, X. Liu
Journal: Cell Biology and Toxicology
Year: 2024

Title: Post‐translational modifications of protein in response to ionizing radiation
Authors: X. Liu, R. Liu, Y. Bai, H. Jiang, X. Fu, S. Ma
Journal: Cell Biochemistry and Function
Year: 2020

Title: The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
Authors: F. Shi, H. Wen, R. Liu, J. Bai, F. Wang, S. Mubarik, X. Liu, Y. Yu, Q. Hong, J. Cao, …
Journal: Global Health Research and Policy
Year: 2021

Title: Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population
Authors: R. Liu, L. Ning, X. Liu, H. Zhang, Y. Yu, S. Zhang, W. Rao, J. Shi, H. Sun, Q. Yu
Journal: Oncotarget
Year: 2017

Title: The challenges of precision radiotherapy technology to the traditional theory of radiobiology
Authors: S. Ma, Z. Liang, Q. Chen, R. Liu, Y. Guo, X. Liu
Journal: Chinese Journal of Radiological Medicine and Protection
Year: 2019

Title: Tumor-associated macrophages in radiotherapy: Mechanisms of polarization, immune regulation and therapeutic strategies
Authors: S. Ma, Z. Liang, X. Liu, R. Liu
Journal: Frontiers in Oncology
Year: 2023

Donglin Sun | Prostate Cancer | Best Researcher Award

Posted on by Pencis

Dr. Donglin Sun | Prostate Cancer | Best Researcher Award

Southern Medical University | China

AUTHOR PROFILE

Scopus

🔬SUN DONGLIN – MEDICAL DOCTOR IN ONCOLOGY 

📚EARLY ACADEMIC PURSUITS 

Sun Donglin began his academic journey at No.1 Middle School of Fuyang, Anhui Province (2005-2008). His strong foundation in science led him to pursue a Bachelor’s Degree in Clinical Medicine at Bengbu Medical College (2008-2013), where he developed a keen interest in oncology. His dedication and passion for medical research culminated in a PhD in Oncology through the Master-Doctor Continuous Program at the Affiliated Cancer Hospital of Guangzhou Medical University (2018-2023). He was recognized as an “Outstanding Graduate Student” and “Excellent Graduate”, a testament to his academic excellence and research contributions.

🏥PROFESSIONAL ENDEAVORS 

Sun Donglin’s clinical training and professional career reflect a steady progression in expertise:

  • 2013 – 2016: Surgical Resident, Third Affiliated Hospital of Sun Yat-sen University – Gained hands-on experience in surgical oncology.
  • 2016 – 2018: Urology Resident Physician, Shenzhen Hospital of Southern Medical University – Developed a specialization in urological oncology.
  • 2023 – Present: Urology Associate Chief Physician, Shenzhen Hospital of Southern Medical University – Achieved Associate Chief Physician Certification in 2020, demonstrating his leadership in urologic oncology and clinical excellence.

🔍RESEARCH FOCUS 

Sun Donglin’s research focuses on two critical areas in oncology:

  1. Mechanisms of Non-Canonical NF-κB Signaling in Renal Fibrosis – Investigating how alternative pathways of NF-κB contribute to fibrosis, which has significant implications for kidney disease treatments.
  2. Drug Resistance Mechanisms in Prostate Cancer – Exploring molecular resistance pathways in prostate cancer to enhance therapeutic strategies and overcome treatment barriers.

💡CONTRIBUTIONS TO SCIENTIFIC RESEARCH 

Sun Donglin has led and participated in several high-impact research projects:

  • Principal Investigator:

    • National Natural Science Foundation of China (Youth Program) – 300,000 RMB (2025-2027) (Approval No.: 82400789)
    • Guangdong Provincial Medical Science and Technology Research Fund – 10,000 RMB (2024-2026) (Approval No.: A2024317)
    • Southern Medical University National Natural Science Foundation Cultivation Program – 100,000 RMB (2024-2026) (Approval No.: 23H3AGZR02)

  • Key Participant in Major Research Projects:

    • National Natural Science Foundation of China Major Research Program Cultivation Project – 680,000 RMB (2020-2022) (Approval No.: 91949102)
    • National Natural Science Foundation of China General Program – 570,000 RMB (2019-2022) (Approval No.: 81874095)

🌍IMPACT AND INFLUENCE 🌍

Sun Donglin’s research has contributed to a deeper understanding of renal fibrosis mechanisms and drug resistance in prostate cancer. His work has the potential to improve therapeutic interventions and patient outcomes, particularly in treatment-resistant prostate cancer cases. His collaborations in major national projects highlight his role as an emerging leader in oncological research.

🏅ACADEMIC CITES AND RECOGNITION 

  • Recognized as an Outstanding Graduate Student and Excellent Graduate during his PhD.
  • His research findings are gaining recognition in top-tier oncology journals, further solidifying his influence in the field.
  • Contributions to multi-million RMB-funded research projects, showcasing his ability to secure competitive grants.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Sun Donglin’s work will shape the future of oncology therapeutics and urological oncology. His research on non-canonical NF-κB signaling could unlock new pathways for renal fibrosis treatment, while his studies on prostate cancer drug resistance could lead to novel therapeutic strategies.

Moving forward, he aims to:
✅ Expand research collaborations internationally to enhance the impact of his studies.
✅ Develop translational therapies targeting NF-κB signaling in fibrosis and prostate cancer.
✅ Mentor young oncologists and researchers to foster the next generation of medical scientists.

🌍CONCLUSION 

Dr. Sun Donglin is a rising leader in oncology research and urological oncology, with a strong foundation in both clinical practice and scientific innovation. His expertise in non-canonical NF-κB signaling in renal fibrosis and drug resistance in prostate cancer has positioned him as a key contributor to the advancement of cancer therapeutics.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression
    Authors: Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., Qian, G., Li, C., Zhang, H., Jiang, Y., Ye, D., Liu, D., Hu, Y., Wang, J., Chen, W., Zhao, Q., Zeng, M., Zhang, J., Wang, L., & Zhang, X
    Journal: Clinical and Translational Medicin
    Year: 2021

 

  • Title: B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3.
    Authors: Qian, G., Jiang, W., Sun, D., Sun, Z., Chen, A., Fang, H., Wang, J., Liu, Y., Yin, Z., Wei, H., Fang, H., & Zhang, X.
    Journal: Cellular & Molecular Immunology
    Year: 2023

 

  • Title: Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-κB Signaling with Antitumor Efficacy
    Authors: Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., Liu, S., Liu, Y., Jiang, Y., Zhu, W., & Zhang, X.
    Journal: Molecular Therapy
    Year: 2025

 

  • Title: LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization.
    Authors: Liang, W., Wu, H., Long, Q., Lin, H., Lv, X., Ma, W., Wu, T., Ai, L., Zheng, Q., Guo, J., Chen, X., Guo, J., & Sun, D..
    Journal: Life Sciences
    Year: 2025

 

  • Title: Integrative analysis of potential diagnostic markers and therapeutic targets for glomerulus-associated diabetic nephropathy based on cellular senescence
    Authors: Sun, D., Wei, S., Wang, D., Zeng, M., Mo, Y., Li, H., Liang, C., Li, L., Zhang, J. W., & Wang, L
    Journal: Frontiers in Immunology
    Year: 2023

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Posted on by Pencis

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Qufu Normal University | China

AUTHOR PROFILE

Scopus

Google Scholar

🏫 EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Feng Li began their academic journey with a solid foundation in the life sciences, focusing on biology and computational biology during their undergraduate and graduate studies. They earned advanced degrees specializing in bioinformatics and oncology-related research, which positioned them at the intersection of biological data analysis and tumor research. Their early years were marked by exceptional performance, earning scholarships and accolades for academic excellence.

💌 PROFESSIONAL ENDEAVORS

Dr. Feng Li currently serves as an Associate Professor at Qufu Normal University in China. They have built a career that bridges teaching, research, and mentorship, shaping the next generation of scientists in the field of tumor biology and bioinformatics. They also collaborate with leading researchers and institutions, contributing to multidisciplinary projects and promoting innovation in their field.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Dr. Li’s primary research focus lies in tumor biology, particularly the application of bioinformatics to understand cancer mechanisms. Their work emphasizes:

  • Identifying biomarkers for cancer diagnostics and therapy.
  • Analyzing genomic and proteomic data to uncover tumor-related pathways.
  • Developing predictive models for patient outcomes using machine learning.

Their groundbreaking research has led to the publication of numerous peer-reviewed articles, advancing knowledge in cancer genomics and computational oncology.

🌍 IMPACT AND INFLUENCE

Through their research, Dr. Feng Li has significantly impacted the scientific community by:

  • Enhancing the understanding of cancer biology.
  • Introducing innovative bioinformatics tools for data analysis.
  • Influencing clinical practices with actionable insights from their studies.

Their work is frequently cited, reflecting their contributions to the broader academic discourse in oncology and bioinformatics.

📊 ACADEMIC CITES

Dr. Li’s publications have garnered widespread recognition, with a growing H-index reflecting their influence in the academic community. Their articles are cited by researchers worldwide, signifying the value and relevance of their findings.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Feng Li’s legacy is marked by their dedication to advancing cancer research and mentoring young scientists. Looking ahead, their focus includes:

  • Expanding research in personalized cancer therapies.
  • Fostering collaborations between bioinformatics and clinical oncology.
  • Inspiring future generations through teaching and research initiatives.

🌟 OTHER IMPORTANT TOPICS

  • Teaching Excellence: Dr. Li is recognized for their engaging teaching methods, integrating real-world research into classroom learning.
  • Community Engagement: Actively participates in academic conferences and workshops, sharing their expertise and fostering knowledge exchange.
  • Interdisciplinary Approach: Their work exemplifies how bioinformatics and oncology can converge to solve complex medical challenges.

🌟CONCLUSION 

Assoc. Prof. Dr. Feng Li has emerged as a pivotal figure in the fields of tumor biology and bioinformatics, blending academic rigor with innovative research to tackle some of the most pressing challenges in oncology. Through their groundbreaking contributions, impactful teaching, and dedication to interdisciplinary collaboration, Dr. Li has left an indelible mark on the scientific community.

 

📊🔬NOTABLE PUBLICATION:
  • 1. SLGCN: Structure-enhanced line graph convolutional network for predicting drug–disease associations
    • Authors: Liu, B.-M., Gao, Y.-L., Li, F., Zheng, C.-H., Liu, J.-X.
    • Journal: Knowledge-Based Systems
    • Year: 2024

    2. A framework for scRNA-seq data clustering based on multi-view feature integration

    • Authors: Li, F., Liu, Y., Liu, J., Ge, D., Shang, J.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2024

    3. KFDAE: CircRNA-Disease Associations Prediction Based on Kernel Fusion and Deep Auto-Encoder

    • Authors: Kang, W.-Y., Gao, Y.-L., Wang, Y., Li, F., Liu, J.-X.
    • Journal: IEEE Journal of Biomedical and Health Informatics
    • Year: 2024

    4. Multi-Affinity network integration based on multi-omics data for tumor stratification

    • Authors: Li, F., Gao, Y., Sun, Z., Shang, J., Liu, J.-X.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2025

    5. A review: simulation tools for genome-wide interaction studies

    • Authors: Shang, J., Xu, A., Bi, M., Li, F., Liu, J.-X.
    • Journal: Briefings in Functional Genomics
    • Year: 2024

Dr. Ohidul Alam | Oncology Case Reports | Best Researcher Award

Posted on by Pencis

Dr. Ohidul Alam | Oncology Case Reports | Best Researcher Award

Jiangsu University | China

Author Profile

Scopus

Google Scholar

🌍 Dr. Ohidul Alam: Postdoctoral Research Fellow and Environmental Innovator 🌱

💧Current Position

  • Postdoctoral Research Fellow, Institute of Environment and Ecology, School of the Environment and Safety Engineering, Jiangsu University

♻Research Focus

Dr. Ohidul Alam is dedicated to advancing environmental sustainability and ecological safety. His primary research interests include:

  • 🌊 Coastal Environment and Wetlands: Investigating microplastics as vectors for antibiotic resistance genes (ARGs) and heavy metals.
  • ♻ Hazardous Waste Management: Treatment and recycling of waste and heavy metals.
  • 💧 Wastewater Treatment and Pollution Control: Developing advanced environmental materials like adsorbents and composites for energy storage and purification.
  • 🧬 Antibiotic Resistance Genes: Exploring ARG mechanisms in ecological systems.

🎓Education 

  • PhD in Environmental Engineering, East China University of Science and Technology, Shanghai, China (2016–2021)
  • MEng in Environmental Engineering, UNEP-Tongji Institute of Environment for Sustainable Development, Tongji University, Shanghai, China (2014–2016)
  • MS in Environmental Science, Institute of Forestry and Environmental Sciences, University of Chittagong, Bangladesh (2010–2011)

🛠Career Snapshot 

  • Postdoctoral Research (2023–Present): Investigating microplastics as vehicles for ARGs and toxic heavy metals in coastal wetlands, assessing ecological and health risks.
  • Environmental Officer (2022–2023): Sustainable Enterprise Project (SEP), Integrated Development Foundation (IDF).
  • Research Associate and Assistant: Contributed to seven major academic and socio-environmental projects.

🖋Publications and Contributions 

  • Published 15 SCI-indexed journal papers, 9 international open-access journal articles, and 13 international conference papers.
  • Authored 3 national journal articles and 3 technical/working papers.
  • Supported colleagues in research, thesis writing, and scientific publications.

🏆Recognition and Awards 

  • Chinese Scholarship Council (CSC) and Marine Scholarship of China (MSC), 2014
  • Tongji University President Scholarship (2nd Prize), 2015, for academic excellence.

🀝Professional Memberships 

  • International Waste Working Group (IWWG)
  • Human Development Foundation (HDF)

🧟Reviewer Roles 

  • Journal of Environmental Management
  • Environmental Research
  • Environment, Development and Sustainability
  • Water Science and Technology

📚Training and Skills Development 

  • Completed advanced training on the Leaching Environmental Assessment Framework (LEAF) for waste treatment and beneficial reuse.

Dr. Alam’s interdisciplinary approach bridges the gap between environmental engineering, sustainable development, and ecological safety. His work continues to inspire progress toward a cleaner, safer world. 🌍✚

🌏 CONCLUSION

Dr. Ohidul Alam exemplifies dedication to environmental sustainability through his groundbreaking research on hazardous waste management, pollution control, and ecological risks posed by microplastics. His extensive academic achievements, impactful publications, and hands-on contributions to global environmental projects highlight his expertise and commitment to creating sustainable solutions for pressing environmental challenges. As a scholar, innovator, and mentor, Dr. Alam continues to pave the way for a cleaner, safer, and more sustainable future. 🌱🌍

📊🔬NOTABLE PUBLICATION:
  • Title: An in-depth review on municipal solid waste management, treatment, and disposal in Bangladesh
    • Authors: Alam, O.; Qiao, X.
    • Journal: Sustainable Cities and Society
    • Year: 2020

 

  • Title: A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh
    • Authors: Alam, O.; Mosharraf, A.
    • Journal: International Journal of Environmental Science and Technology
    • Year: 2020

 

  • Title: Influences of chemically controlled Ca-bearing minerals in chitosan on Pb²⁺ removal efficiency
    • Authors: Alam, O.; Qiao, X.
    • Journal: Journal of Environmental Health Science and Engineering
    • Year: 2020

 

  • Title: The effect of Ca-bearing contents in chitosan on Pb²⁺, Cd²⁺, and Cu²⁺ adsorption and its adsorption mechanism
    • Authors: Alam, O.; Qiao, X.; Nath, T.K.
    • Journal: Journal of Environmental Health Science and Engineering
    • Year: 2020

 

  • Title: Remediation of heavy metals polluted soil environment: A critical review on biological approaches
    • Authors: Zheng, X.; Lin, H.; Du, D.; Jiang, S.; Li, J.
    • Journal: Ecotoxicology and Environmental Safety
    • Year: 2024

Dr. Wang Tian | Neck Cancer | Best Researcher Award

Posted on by Pencis

Dr. Wang Tian | Neck Cancer | Best Researcher Award

Fudan University | China

AUTHOR PROFILE

Scopus

🎓 EARLY ACADEMIC PURSUITS

Dr. Wang Tian embarked on his academic journey in the field of medical sciences, specializing in Otolaryngology with a focus on Head and Neck Oncology. His foundational education was marked by excellence, having graduated from one of China’s top medical institutions. He further pursued specialized training in Head and Neck Surgery, equipping himself with cutting-edge knowledge and skills. His early research was primarily centered on the identification and treatment of head and neck malignancies, laying the groundwork for a career dedicated to innovation in cancer therapy.

🏥 PROFESSIONAL ENDEAVORS

Dr. Tian is currently the Head of the Department of Head and Neck Oncology at the EENT Hospital of Fudan University, a premier institution for Ear, Nose, Throat, and specialized oncology treatments in China. Under his leadership, the department has become a hub for advanced clinical care and groundbreaking research. He is actively involved in surgical oncology, leading numerous high-risk procedures and developing new treatment protocols for cancers of the head, neck, and thyroid. His professional endeavors extend to collaborations with international oncology boards and contributing to the establishment of global best practices in the field.

💡 CONTRIBUTIONS AND RESEARCH FOCUS ON NECK CANCER

Dr. Wang Tian’s contributions to medical science, particularly in head and neck oncology, are vast and influential. His research primarily focuses on early detection, personalized treatment strategies, and minimally invasive surgical techniques. One of his notable achievements is the development of targeted therapy approaches that enhance the efficacy of traditional treatments like radiotherapy and chemotherapy. He has also contributed significantly to the study of immunotherapy for head and neck cancers, paving the way for more personalized, patient-centered treatment regimens.

🌍 IMPACT AND INFLUENCE

Dr. Tian’s work has had a profound impact on the field of oncology, both in China and globally. His research papers, published in prestigious international journals, have been widely cited and have influenced treatment protocols worldwide. He has also mentored numerous young surgeons and oncologists, many of whom have gone on to make significant contributions in their own right. His leadership at EENT Hospital has solidified the institution’s reputation as a leader in cancer treatment, particularly for complex head and neck cases.

📚 ACADEMIC CITATIONS

Dr. Wang Tian’s research has been cited extensively in academic literature, particularly in the fields of oncology, surgery, and immunotherapy. His most highly cited works pertain to innovations in head and neck cancer treatment, especially regarding new surgical techniques and personalized therapy models. His h-index reflects a significant influence in the academic and medical community, demonstrating his role as a leading expert in his field.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Wang Tian’s legacy is one of innovation, dedication, and a commitment to improving patient outcomes. He is regarded as a pioneer in head and neck cancer treatment, with a long-standing impact that will influence future generations of oncologists and surgeons. Looking forward, Dr. Tian continues to push the boundaries of research in cancer immunotherapy and genetic-based treatments, with an eye on developing even more effective and less invasive therapeutic options. His ongoing work promises to further revolutionize the field and offer hope to patients worldwide.

🔔 CONCLUSION

Dr. Wang Tian stands as a prominent figure in the realm of head and neck oncology, with his contributions significantly shaping both clinical practices and research directions. From his early academic pursuits to his leadership at the EENT Hospital of Fudan University, his commitment to advancing cancer treatments is evident. Dr. Tian’s innovative research in targeted therapies, immunotherapy, and minimally invasive surgery has not only improved patient outcomes but also set new standards in oncology care. His legacy, marked by mentorship, extensive publications, and groundbreaking discoveries, continues to inspire future generations. As he moves forward, his future contributions will likely lead to even more transformative breakthroughs, cementing his place as a global leader in head and neck cancer treatment.

 

📊🔬NOTABLE PUBLICATION:

 

  • Title: The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma
    Authors: Wang, T., Zhang, D., Tang, D., Lu, L.-M., Tao, L.
    Journal: Journal of Cancer Research and Clinical Oncology
    Year: 2023

 

  • Title: Peripheral lymphocyte count as an indicator of radiotherapy effectiveness in hypopharyngeal squamous cell carcinoma
    Authors: Lin, H., Gao, C., Heng, Y., Wu, C., Tao, L.
    Journal: Clinical Otolaryngology
    Year: 2024

 

  • Title: Neoadjuvant chemotherapy for organ preservation in sinonasal squamous cell carcinoma
    Authors: Wang, T., Li, Y., Wang, L., Zhao, K., Song, X.
    Journal: European Archives of Oto-Rhino-Laryngology
    Year: 2024

 

  • Title: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial
    Authors: Gong, H., Tian, S., Ding, H., Wang, S., Zhou, L.
    Journal: Nature Communications
    Year: 2024

 

  • Title: Surgery for adult head and neck rhabdomyosarcoma: A retrospective report from one institution
    Authors: Wang, T., Wang, J., Tang, T., Li, Y., Song, X.
    Journal: International Forum of Allergy and Rhinology
    Year: 2024

Ms. Hao Li – Tumor Immunology – Young Scientist Award

Posted on by Pencis

Ms. Hao Li - Tumor Immunology - Young Scientist Award

First Hospital of China Medical University - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Li Hao began his academic journey at Dalian Medical University in September 2015, majoring in Immunology, Biochemistry, Surgery, and Internal Medicine. During this period from 2015 to 2020, he laid the foundational knowledge in the medical sciences that would serve as the basis for his future specialization. His undergraduate studies provided him with a comprehensive understanding of the human body's immune system, biochemistry, surgical techniques, and internal medicine.Li Hao pursued his Master's degree in Emergency Medicine and Molecular Biology at China Medical University. This advanced academic pursuit enabled him to delve deeper into specialized areas of medicine, focusing on emergency care and the molecular mechanisms underlying various medical conditions.

PROFESSIONAL ENDEAVORS

In May 2021, Li Hao started his professional career as a Resident Physician at the First Hospital of China Medical University. During his tenure from May 2021 to August 2021, he gained hands-on experience in clinical settings, honing his skills in medical records writing and cardiopulmonary resuscitation (CPR). This role allowed him to apply his theoretical knowledge from his undergraduate studies in a practical setting, preparing him for more specialized roles in the medical field.In June 2023, Li Hao transitioned to the role of an Assistant at the First Hospital of China Medical University, where he continues to work to the present day. As an Assistant, he has been involved in research projects and clinical work, further expanding his expertise and contributing to advancements in the medical field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Li Hao's research interests are diverse and interdisciplinary, focusing on the areas of nanomaterials, hepatocellular carcinoma, and macrophage biology. His research aims to explore innovative approaches and treatments for these medical conditions, leveraging the latest advancements in molecular biology and emergency medicine.

IMPACT AND INFLUENCE

Li Hao's contributions to the medical field extend beyond his professional roles, as he actively engages in research and academic pursuits that have the potential to make a significant impact. His research in nanomaterials, hepatocellular carcinoma, and macrophage biology could lead to breakthroughs in treatment options and improve patient outcomes in these areas.

ACADEMIC SITES

Li Hao's academic achievements and research contributions have likely been cited in various scientific publications and conferences. His interdisciplinary research in nanomaterials, hepatocellular carcinoma, and macrophage biology demonstrates his commitment to advancing medical science and contributing valuable insights to the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Li Hao continues to pursue his career in emergency medicine and molecular biology, his interdisciplinary research and clinical experience will undoubtedly leave a lasting legacy in the medical field. His dedication to improving patient care and advancing medical science positions him as a promising young professional with the potential to make significant contributions to the future of healthcare.

NOTABLE PUBLICATIONS

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.  2024

Glutamate Chemical Exchange Saturation Transfer (GluCEST) MRI to Evaluate the Rapid Antidepressant Effects of Ketamine in the Hippocampus of Rat Depression Model. 2024 (1)

Preclinical multi-physiologic monitoring of immediate-early responses to diverse treatment strategies in breast cancer by optoacoustic imaging. 2024

Glutamate alterations in the premature infant brain during different gestational ages with glutamate chemical exchange saturation transfer imaging: a pilot study. 2023 (1)

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups. 2023 (1)

 

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023